This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Humana (HUM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Humana (HUM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Humana (HUM) Closes $2.8B Kindred Hospice Divestment to CD&R
by Zacks Equity Research
Humana (HUM) retaining the remaining 40% stake will likely enable it to gain from the standalone company's long-term success.
UnitedHealth (UNH) Unit Adds Features to Surest Plans
by Zacks Equity Research
UnitedHealth Group's (UNH) arm UnitedHealthcare advances Surest plans by including features to lure more employers into opting for the attractive package and bolster its geographic reach.
Should Value Investors Buy Humana (HUM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Select Medical (SEM) Shares Dip on Q2 Earnings & Revenue Miss
by Zacks Equity Research
Select Medical's (SEM) second-quarter earnings take a hit from escalating expenses and reduced admissions within the Critical Illness Recovery Hospital segment.
Acadia Healthcare (ACHC) Stock Up 3% on Q2 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) second-quarter results benefit from a strong-performing U.S. business. A raised 2022 guidance with respect to EPS bodes well.
3 Great Stocks to Buy in August for Safety and Long-Term Growth
by Benjamin Rains
The episode focuses on three stocks--Humana, Merck, and Dollar Tree--that have proven they can climb during 2022's falling market and operate businesses that are likely to withstand any economic downturn or possible recession.
Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Cigna (CI) Q2 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Cigna's (CI) second-quarter results indicate solid membership growth plus sound contributions from Evernorth and Cigna Healthcare segments. An upped 2022 EPS outlook remains noteworthy.
DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View
by Zacks Equity Research
DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Zacks Investment Ideas feature highlights: Humana and Centene
by Zacks Equity Research
Humana and Centene are part of Zacks Investment Ideas article.
Avantor's (AVTR) Stock Falls 8.8% Since Q2 Earnings Miss
by Zacks Equity Research
Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.
Stick With These Health Care Leaders in the Second Half of 2022
by Bryan Hayes
There are steps we can take to mitigate the volatility and benefit our portfolio as we move further into the second half of the year.
Integer Holdings (ITGR) Q2 Earnings Miss, FY22 View Revised
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Molina Healthcare (MOH) Q2 Earnings Beat, Hikes '22 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results gain from membership growth within its Medicaid and Medicare lines of business. A hiked adjusted EPS guidance for 2022 is noteworthy.
Humana (HUM) Q2 Earnings Beat Estimates, Ups '22 EPS View
by Zacks Equity Research
Humana's (HUM) second-quarter earnings benefit from higher premiums and strong individual Medicare Advantage membership growth. A hiked adjusted EPS guidance for 2022 is noteworthy.
Investors Await For Key Fed FOMC Decision
by Zacks Equity Research
Investors Await For Key Fed FOMC Decision.
Pre-Markets Up Ahead of Fed Announcement
by Mark Vickery
The Dow is +162 points at this hour, the S&P 500 is +36 and the Nasdaq is far ahead of the field: +188 points.
Humana (HUM) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 13.04% and 1.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?